A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs Omadacycline (Primary)
- Indications Nontuberculous mycobacterium infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Paratek Pharmaceuticals
- 08 Nov 2024 According to a Paratek Pharmaceuticals media release, Kevin Winthrop, M.D., M.P.H is the Principal Investigator in the study. And Analysis of study data is ongoing and the complete data from this study will be presented in the future and published in a peer-reviewed journal.
- 08 Nov 2024 Results presented in the Paratek Pharmaceuticals Media Release.
- 14 Oct 2024 According to a Paratek Pharmaceuticals media release, a new data from this study will be presented at IDWeek 2024, Oct. 16-19 at the Los Angeles Convention Center in Los Angeles, CA.